3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Management of hepatitis B: our practice and how it relates to the guidelines.

      1 , 1 , 2
      Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
      AASLD, AFP, ALT, APASL, American Association for the Study of Liver Diseases, Antiviral Therapy, Asian Pacific Association for the Study of the Liver, CHB, Chronic Hepatitis B, EASL, European Association for the Study of the Liver, HBV, HBeAg, HBsAg, HCC, Hepatitis B Guidelines, IFN, Management, NUC, PEG-IFN, ULN, alanine aminotransferase, anti-HBc, anti-HBe, chronic hepatitis B, hepatitis B core antibody, hepatitis B e antibody, hepatitis B e antigen, hepatitis B surface antigen, hepatitis B virus, hepatocellular carcinoma, interferon, nucleos(t)ide analogue, pegylated-interferon, upper limit of normal, α-fetoprotein

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Seven drugs have been approved for the treatment of chronic hepatitis B. Antiviral treatment has been shown to be effective in suppressing hepatitis B virus replication, decreasing inflammation and fibrosis in the liver, and preventing progression of liver disease. However, current medications do not eradicate hepatitis B virus; therefore, a key question is which patients need to start treatment and which patients can be monitored. Professional societies have developed guidelines to assist physicians in recognition, diagnosis, and optimal management of patients with chronic hepatitis B. These guidelines suggest preferred approaches, and physicians are expected to exercise clinical judgment to determine the most appropriate management based on the circumstances of the individual patient. This article reviews recommendations in hepatitis B guidelines and the basis for those recommendations, and we discuss what we do in our practice to illustrate factors that may influence decisions regarding hepatitis B management.

          Related collections

          Author and article information

          Journal
          Clin. Gastroenterol. Hepatol.
          Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
          1542-7714
          1542-3565
          Jan 2014
          : 12
          : 1
          Affiliations
          [1 ] Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, Michigan.
          [2 ] Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, Michigan. Electronic address: aslok@umich.edu.
          Article
          S1542-3565(13)00606-X
          10.1016/j.cgh.2013.04.036
          23660419
          9d7dbcf7-2bad-4435-9702-3f21937c4ce2
          Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.
          History

          AASLD,AFP,ALT,APASL,American Association for the Study of Liver Diseases,Antiviral Therapy,Asian Pacific Association for the Study of the Liver,CHB,Chronic Hepatitis B,EASL,European Association for the Study of the Liver,HBV,HBeAg,HBsAg,HCC,Hepatitis B Guidelines,IFN,Management,NUC,PEG-IFN,ULN,alanine aminotransferase,anti-HBc,anti-HBe,chronic hepatitis B,hepatitis B core antibody,hepatitis B e antibody,hepatitis B e antigen,hepatitis B surface antigen,hepatitis B virus,hepatocellular carcinoma,interferon,nucleos(t)ide analogue,pegylated-interferon,upper limit of normal,α-fetoprotein

          Comments

          Comment on this article